Northumbria U
Newcastle, Tyne, NE1 7RU, United Kingdom
NCT Number: NCT07400614
The primary purpose of the research is to evaluate in healthy adults the time course effects of energy drink formulas containing 120 mg caffeine with varying levels of taurine and b vitamins on subjective alertness in the presence of cognitive load assessed hourly up to 5 hours post dose
Looking for future studies?
Notify Me18 year–49 year
All sexes
Interventional
Not applicable
Newcastle, Tyne, NE1 7RU, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Caffeine with varying amounts of taurine and B vitamins
Base with 0 mg caffeine, taurine, vitamins
Time frame: Change from baseline Time 0 to 240 minutes post-dose
Subjective 'alert' and 'tired' ratings combined to create a composite alertness factor. Alert ratings assessed by placing an 'x' on a line representing 0-100 to match their current state; tired ratings assessed by placing an 'x' on a line representing 0-100 to match their current state. Higher alert ratings represent a better outcome, higher tired ratings represent a worse outcome and are reversed to create the composite score, which is the average of the two scales and is scored 0-100 with higher scores representing a better outcome.
Time frame: Change from baseline Time 0 to 60, 120, 180, 240 & 300 minutes post-dose
Subjective 'alert' and 'tired' ratings combined to create a composite alertness factor. Alert ratings assessed by placing an 'x' on a line representing 0-100 to match their current state; tired ratings assessed by placing an 'x' on a line representing 0-100 to match their current state. Higher alert ratings represent a better outcome, higher tired ratings represent a worse outcome and are reversed to create the composite score, which is the average of the two scales and is scored 0-100 with higher scores representing a better outcome.
Time frame: Change from baseline Time 0 to 60, 120, 180, 240 & 300 minutes post-dose
Subjective ratings assessed by placing an 'x' on a line representing 0-100 to match their current state (relaxed, alert, jittery, tired, tense, headache, overall mood, mental fatigue)
Time frame: Change from baseline Time 0 to 60, 120, 180, 240 & 300 minutes post-dose
Subjective 'relaxed' and 'tense' ratings combined to create a composite tension factor. Relaxed ratings assessed by placing an 'x' on a line representing 0-100 to match their current state; tense ratings assessed by placing an 'x' on a line representing 0-100 to match their current state. Higher tense ratings represent a worse outcome, higher relaxed ratings represent a better outcome and are reversed to create the composite score, which is the average of the two scales and is scored 0-100 with higher scores representing a worse outcome.
Time frame: Change from baseline Time 0 to 60, 120, 180, 240 & 300 minutes post-dose. Each test has duration ~21 minutes )
Cognitive function - attention measured as reaction time (in milliseconds), with a lower score indicating better performance using the Computerised Mental Performance Assessment System (COMPASS)
Time frame: Change from baseline Time 0 to 60, 120, 180, 240 & 300 minutes post-dose. Each test has duration ~21 minutes )
Cognitive function - attention measured as a percentage, with a higher score indicating better performance using the Computerised Mental Performance Assessment System (COMPASS)
Time frame: Change from baseline Time 0 to 60, 120, 180, 240 & 300 minutes post-dose. Each test has duration ~21 minutes )
Cognitive function - attention measured as reaction time (in milliseconds), with a lower score indicating better performance using the Computerised Mental Performance Assessment System (COMPASS)
Time frame: Change from baseline Time 0 to 60, 120, 180, 240 & 300 minutes post-dose. Each test has duration ~21 minutes )
Cognitive function - attention measured as number of errors, with a lower score indicating better performance using the Computerised Mental Performance Assessment System (COMPASS)
Time frame: Change from baseline Time 0 to 60, 120, 180, 240 & 300 minutes post-dose. Each test has duration ~21 minutes )
Cognitive function - attention measured as a percentage, with a higher score indicating better performance using the Computerised Mental Performance Assessment System (COMPASS)
Time frame: Change from baseline Time 0 to 60, 120, 180, 240 & 300 minutes post-dose. Each test has duration ~21 minutes )
Cognitive function - attention measured as reaction time (in milliseconds), with a lower score indicating better performance using the Computerised Mental Performance Assessment System (COMPASS)
Time frame: Change from baseline Time 0 to 60, 120, 180, 240 & 300 minutes post-dose. Each test has duration ~21 minutes )
Cognitive function - attention measured as a percentage, with a higher score indicating better performance using the Computerised Mental Performance Assessment System (COMPASS)
Time frame: Change from baseline Time 0 to 60, 120, 180, 240 & 300 minutes post-dose. Each test has duration ~21 minutes )
Cognitive function - attention measured as reaction time (in milliseconds), with a lower score indicating better performance using the Computerised Mental Performance Assessment System (COMPASS)
Time frame: Change from baseline Time 0 to 60, 120, 180, 240 & 300 minutes post-dose. Each test has duration ~21 minutes )
Cognitive function - attention measured as number of errors, with a lower score indicating better performance using the Computerised Mental Performance Assessment System (COMPASS)
PepsiCo Global R&D
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06785142
Alertness, Mood
London, United Kingdom
View Trial DetailsNCT05481424
Alertness, Cognitive Performance
Tempe, Arizona, United States
View Trial DetailsNCT05096780
Alertness
Dilworth, Minnesota, United States
View Trial DetailsNCT04975802
Alertness, Behavior
Newcastle upon Tyne, United Kingdom
View Trial Details